sebelipase

1 Drug classified under this active ingredient

recombinant human lysosomal acid lipase. sebelipase 2 mg/ml.
VIAL Conc. for sol. for infus. 1 X 10 ml
Pts. with rapidly progress. LAL defic. presenting within the first 6 months of life: starting dose is either 1 mg/kg or 3 mg/kg admin. as IV infus. 1 X week, depending on the clin. status of the pt.
Ped. and adult pts. with LAL defic:1 mg/kg administered as IV infus. once every other week. See lit.
For long-term enzyme replacement ther.(ERT) in pts. of all ages with lysosomal acid lipase (LAL) deficiency.
C/I: Hypersens.